Mumbai, May 28: Hikal Limited, a leading global life sciences company, today announced its audited financial results for the quarter and financial year ended March 31, 2026.
Consolidated Q4 FY26 Financial Highlights
Revenue from Operations stood at ₹519.4 crore, representing a sequential growth of 5% over the preceding quarter (₹494.3 crore).
Profit After Tax (PAT) recovered to ₹14.4 crore for the quarter, compared to a net loss of ₹5.9 crore in Q3 FY26.
EBITDA before exceptional items was recorded at ₹55.4 crore, showing strong sequential improvement.
The Board of Directors has recommended a final dividend of 20% (₹0.40 per equity share), bringing the total dividend for FY26 to 30% (₹0.60 per share).
Segment Performance
Crop Protection: The segment demonstrated robust growth with Q4 revenue reaching ₹227.8 crore, up from ₹201.1 crore in the corresponding period last year.
Pharmaceuticals: The segment reported Q4 revenue of ₹291.6 crore. Performance during the year was impacted by a USFDA warning letter issued in August 2025 regarding the company’s Jigani facility.
Strategic Progress and Exceptional Items
The company’s annual profitability was impacted by one-time strategic and regulatory accounting adjustments totaling ₹85.1 crore. These include:
Plant Repurposing: An impairment charge of ₹47.1 crore was recorded as the company decided to repurpose an existing manufacturing plant to enable a different range of products, aligning with its long-term strategic goals.
Labour Code Compliance: An incremental impact of ₹38.0 crore was recognized due to the notification of new Government of India Labour Codes affecting employee benefit provisions.
Management Commentary
The company continues to focus on operational excellence and navigating regulatory challenges. While the year-on-year profit decline of 71% in Q4 (from ₹50.2 crore in Q4 FY25 to ₹14.4 crore) reflects these one-off costs and pharmaceutical headwinds, the sequential recovery in revenue and profitability signals a positive trajectory for the upcoming fiscal year.
Board Update
The Board has approved the appointment of Mr. Sandip Parikh as an Additional Independent Director for a term of five years, effective May 27, 2026, subject to shareholder approval. Mr. Parikh brings over 35 years of experience in audit, taxation, and transaction advisory.